PMID- 31886190
OWN - NLM
STAT- MEDLINE
DCOM- 20200514
LR  - 20220412
IS  - 2314-6141 (Electronic)
IS  - 2314-6133 (Print)
VI  - 2019
DP  - 2019
TI  - Propranolol Treatment for Infantile Hemangiomas: Short-Term Adverse Effects and 
      Follow-Up to Age Two.
PG  - 2728952
LID - 10.1155/2019/2728952 [doi]
LID - 2728952
AB  - OBJECTIVE: To analyse the short-term adverse effects (AEs) of propranolol in the 
      treatment of infantile hemangiomas (IHs) and their relevant factors, as well as 
      the relationship between child growth and propranolol. METHODS: A total of 506 
      patients with confirmed or suspected IHs were enrolled, and a total of 439 cases 
      were included in the study. Short-term AEs were analysed using single-factor 
      analysis and binary logistic regression. Out of 439 patients, 292 were enrolled 
      to examine the effect of propranolol on 2-year-olds' height and body weight (BW), 
      by comparison with reference range and among groups. Spearman rank correlation 
      analysis was used to determine the relationship between BW, height, and duration 
      of propranolol treatment. RESULTS: Among 439 patients, 70 (16.0%) experienced 
      AEs. Among them, 48 had gastrointestinal (GI) symptoms, 23 had central nervous 
      system (CNS) symptoms, 8 had both symptoms above, and 7 had other symptoms. Most 
      of the AEs occurred on the starting day (day 0), and 6 children's AEs were 
      transient. Starting age of no older than 3 months led to more CNS symptoms, and 
      starting age of older than 3 months was a protective factor against CNS symptoms, 
      with an OR value of 0.303 (0.117-0.783). Height and BW of 292 two-year-old 
      children were no less than the reference levels, although those of 3 females and 
      1 male were less than the average -2 standard deviation (-2SD). The height and BW 
      of the children at the age of two was not related to the length of time of 
      propranolol treatment. CONCLUSION: Oral propranolol has a good tolerance in the 
      treatment of IHs. Oral propranolol exerts more adverse effects on the CNS of 
      lower age children, and it has exhibited no effect on the growth of two-year-old 
      children.
CI  - Copyright (c) 2019 Xueqing Li et al.
FAU - Li, Xueqing
AU  - Li X
AD  - Department of Plastic Surgery, Shandong Provincial Hospital Affiliated to 
      Shandong University, Jinan 250000, China.
FAU - Yang, Kun
AU  - Yang K
AD  - Department of Plastic Surgery, Shandong Provincial Hospital Affiliated to 
      Shandong University, Jinan 250000, China.
FAU - Li, Hongwen
AU  - Li H
AD  - Department of Plastic Surgery, Shandong Provincial Hospital Affiliated to 
      Shandong University, Jinan 250000, China.
FAU - Huo, Ran
AU  - Huo R
AUID- ORCID: 0000-0002-3513-1073
AD  - Department of Plastic Surgery, Shandong Provincial Hospital Affiliated to 
      Shandong University, Jinan 250000, China.
LA  - eng
PT  - Journal Article
DEP - 20191125
PL  - United States
TA  - Biomed Res Int
JT  - BioMed research international
JID - 101600173
RN  - 9Y8NXQ24VQ (Propranolol)
SB  - IM
MH  - Body Height/drug effects
MH  - Body Weight/drug effects
MH  - Central Nervous System/drug effects/pathology
MH  - Child
MH  - Child, Preschool
MH  - Drug-Related Side Effects and Adverse Reactions/classification/*pathology
MH  - Female
MH  - Gastrointestinal Tract/drug effects/pathology
MH  - Hemiplegia/complications/*drug therapy/pathology
MH  - Humans
MH  - Iatrogenic Disease/prevention & control
MH  - Infant
MH  - Male
MH  - Propranolol/*administration & dosage/adverse effects
MH  - Treatment Outcome
PMC - PMC6899275
COIS- The authors declare that there are no conflicts of interest regarding the 
      publication of this paper.
EDAT- 2019/12/31 06:00
MHDA- 2020/05/15 06:00
PMCR- 2019/11/25
CRDT- 2019/12/31 06:00
PHST- 2019/04/19 00:00 [received]
PHST- 2019/07/24 00:00 [revised]
PHST- 2019/08/08 00:00 [accepted]
PHST- 2019/12/31 06:00 [entrez]
PHST- 2019/12/31 06:00 [pubmed]
PHST- 2020/05/15 06:00 [medline]
PHST- 2019/11/25 00:00 [pmc-release]
AID - 10.1155/2019/2728952 [doi]
PST - epublish
SO  - Biomed Res Int. 2019 Nov 25;2019:2728952. doi: 10.1155/2019/2728952. eCollection 
      2019.